AVONEX- interferon beta-1a kit AVONEX PEN- interferon beta-1a injection, solution AVONEX- interferon beta-1a injection, soluti United States - English - NLM (National Library of Medicine)

avonex- interferon beta-1a kit avonex pen- interferon beta-1a injection, solution avonex- interferon beta-1a injection, soluti

biogen inc. - interferon beta-1a (unii: xro4566q4r) (interferon beta-1a - unii:xro4566q4r) - interferon beta-1a 30 ug in 0.5 ml - avonex is indicated for the treatment of relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. avonex is contraindicated in patients with a history of hypersensitivity to natural or recombinant interferon beta, or any other component of the formulation [see warnings and precautions (5.3)] . the formerly available lyophilized vial formulation of avonex is contraindicated in patients with a history of hypersensitivity to albumin (human). risk summary data from a large population-based cohort study, as well as other published studies over several decades, have not identified a drug-associated risk of major birth defects with the use of interferon beta products during early pregnancy. findings regarding a potential risk for low birth weight or miscarriage with the use of interferon beta products in pregnancy have been inconsistent (see data). in a study in pregnant monkeys, administration of interfer

PLEGRIDY- peginterferon beta-1a injection, solution PLEGRIDY PEN- peginterferon beta-1a injection, solution PLEGRIDY- peginter United States - English - NLM (National Library of Medicine)

plegridy- peginterferon beta-1a injection, solution plegridy pen- peginterferon beta-1a injection, solution plegridy- peginter

biogen inc. - peginterferon beta-1a (unii: i8309403r0) (peginterferon beta-1a - unii:i8309403r0) - peginterferon beta-1a 94 ug in 0.5 ml - plegridy is indicated for the treatment of relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. plegridy is contraindicated in patients with a history of hypersensitivity to natural or recombinant interferon beta or peginterferon, or any other component of plegridy [see warnings and precautions ( 5.3)] . risk summary data from a large population-based cohort study, as well as other published studies over several decades, have not identified a drug-associated risk of major birth defects with the use of interferon beta products during early pregnancy. findings regarding a potential risk for low birth weight or miscarriage with the use of interferon beta products in pregnancy have been inconsistent (see data). in a study in pregnant monkeys, administration of interferon beta during pregnancy resulted in an increased rate of abortion (see data ). in the u.s. general population, the estimated backgro

REBIF- interferon beta-1a kit REBIF REBIDOSE- interferon beta-1a kit REBIF- interferon beta-1a injection, solution REBIF- in United States - English - NLM (National Library of Medicine)

rebif- interferon beta-1a kit rebif rebidose- interferon beta-1a kit rebif- interferon beta-1a injection, solution rebif- in

emd serono, inc. - interferon beta-1a (unii: xro4566q4r) (interferon beta-1a - unii:xro4566q4r) - interferon beta-1a 8.8 ug in 0.2 ml - rebif is indicated for the treatment of relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. rebif is contraindicated in patients with a history of hypersensitivity to natural or recombinant interferon beta, human albumin, or any other component of the formulation. risk summary data from a large population-based cohort study, as well as other published studies over several decades, have not identified a drug-associated risk of major birth defects with the use of interferon beta during early pregnancy. findings regarding a potential risk for low birth weight or miscarriage with the use of interferon beta in pregnancy have been inconsistent (see data) . it is unclear whether, as a class of products, administration of interferon beta therapies to pregnant animals at doses greater than those used clinically results in an increased rate of abortion. the potential for rebif to have adverse effects on em

REBIF 22 MCG Israel - English - Ministry of Health

rebif 22 mcg

merck serono ltd - interferon beta 1a - solution for injection - interferon beta 1a 44 mcg/ml - interferon beta-1a - interferon beta-1a - rebif (interferone beta-1a) is indicated for the treatment of patients with relapsing forms of multiple sclerosis to decrease the frequency of clinical exacerbations and delay the accumulation of physical disability. efficacy of rebif in chronic progressive multiple sclerosis has not been established.

PLEGRIDY peginterferon beta-1a (rch) 63 microgram/0.5 mL and 94 microgram/0.5 mL solution for injection pre-filled pen TITRATION PACK Australia - English - Department of Health (Therapeutic Goods Administration)

plegridy peginterferon beta-1a (rch) 63 microgram/0.5 ml and 94 microgram/0.5 ml solution for injection pre-filled pen titration pack

biogen australia pty ltd - peginterferon beta-1a, quantity: 94 microgram - injection, solution - excipient ingredients: arginine hydrochloride; water for injections; sodium acetate trihydrate; polysorbate 20; glacial acetic acid - plegridy is indicated for the treatment of relapsing forms of multiple sclerosis (ms) (see clinical trials).

PLEGRIDY peginterferon beta-1a (rch) 125 microgram/0.5 mL solution for injection pre-filled syringe Australia - English - Department of Health (Therapeutic Goods Administration)

plegridy peginterferon beta-1a (rch) 125 microgram/0.5 ml solution for injection pre-filled syringe

biogen australia pty ltd - peginterferon beta-1a, quantity: 125 microgram - injection, solution - excipient ingredients: sodium acetate trihydrate; water for injections; glacial acetic acid; arginine hydrochloride; polysorbate 20 - plegridy is indicated for the treatment of relapsing forms of multiple sclerosis (ms) (see clinical trials).

PLEGRIDY peginterferon beta-1a (rch) 63 microgram/0.5 mL and 94 microgram/0.5 mL solution for injection pre-filled syringe TITRATION PACK Australia - English - Department of Health (Therapeutic Goods Administration)

plegridy peginterferon beta-1a (rch) 63 microgram/0.5 ml and 94 microgram/0.5 ml solution for injection pre-filled syringe titration pack

biogen australia pty ltd - peginterferon beta-1a, quantity: 94 microgram - injection, solution - excipient ingredients: glacial acetic acid; polysorbate 20; arginine hydrochloride; sodium acetate trihydrate; water for injections - plegridy is indicated for the treatment of relapsing forms of multiple sclerosis (ms) (see clinical trials).

PLEGRIDY peginterferon beta-1a (rch) 125 microgram/0.5 mL solution for injection pre-filled pen Australia - English - Department of Health (Therapeutic Goods Administration)

plegridy peginterferon beta-1a (rch) 125 microgram/0.5 ml solution for injection pre-filled pen

biogen australia pty ltd - peginterferon beta-1a, quantity: 125 microgram - injection, solution - excipient ingredients: sodium acetate trihydrate; glacial acetic acid; water for injections; polysorbate 20; arginine hydrochloride - plegridy is indicated for the treatment of relapsing forms of multiple sclerosis (ms) (see clinical trials).

REBIF 44 interferon beta-1a (rch) 132 microgram/1.5mL solution for injection multidose cartridge Australia - English - Department of Health (Therapeutic Goods Administration)

rebif 44 interferon beta-1a (rch) 132 microgram/1.5ml solution for injection multidose cartridge

merck healthcare pty ltd - interferon beta-1a, quantity: 88 microgram/ml - injection, solution - excipient ingredients: methionine; acetic acid; mannitol; poloxamer; water for injections; benzyl alcohol; sodium hydroxide - rebif is indicated for the treatment of: ? patients with a single demyelinating event in the central nervous system with an active inflammatory process, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite multiple sclerosis. high risk can be inferred from cerebral mri with 2 or more lesions suggestive of demyelination.,? ambulatory patients with multiple sclerosis who have experienced two or more relapses within the last 2 years. rebif therapy should not be initiated in secondary progressive ms patients who no longer experience relapses.?

REBIF 44 interferon beta-1a (rch) 44 microgram/0.5mL injection pre-filled syringe Australia - English - Department of Health (Therapeutic Goods Administration)

rebif 44 interferon beta-1a (rch) 44 microgram/0.5ml injection pre-filled syringe

merck healthcare pty ltd - interferon beta-1a, quantity: 88 microgram/ml - injection, solution - excipient ingredients: benzyl alcohol; water for injections; sodium hydroxide; acetic acid; methionine; poloxamer; mannitol - rebif is indicated for the treatment of: ? patients with a single demyelinating event in the central nervous system with an active inflammatory process, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite multiple sclerosis. high risk can be inferred from cerebral mri with 2 or more lesions suggestive of demyelination.,? ambulatory patients with multiple sclerosis who have experienced two or more relapses within the last 2 years. rebif therapy should not be initiated in secondary progressive ms patients who no longer experience relapses.?